AbbVie ABT-88 Expanded Access to Veliparib
- Result Type
- clinical trial
This is an expanded access program (EAP) for eligible participants.
You are viewing results from Research and Clinical Trials.
9results found for:
This is an expanded access program (EAP) for eligible participants.
Status: Active, Recruiting
The purpose of this study is to find out how genetics, biologics and behavior might contribute to
Status: Active, Recruiting
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Fola
Status: Active, Recruiting
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primar
Status: Active, Not Recruiting
Pegylated Liposomal Doxorubicin Hydrochloride W/Atezolizumab and/or Bevacizumab in Treating Patients W/Recurrent Ovarian,Fallopian Tube,or Primary Peritoneal Ca
Status: Active, Recruiting
Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / IN
Status: Active, Recruiting
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active, Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, lymphoma, and myeloma
Status: Active, Recruiting
Check-ups, screenings and sick visits for adults and children.
Expertise and advanced technologies in all areas of medicine.
For serious accidents, injuries and conditions that require immediate medical care.
After-hours, weekend and holiday services.
Convenient walk-in care clinics for your non-urgent health needs.
We use cookies to give you the best possible user experience. By continuing to use the site, you agree to the use of cookies. Privacy Policy Cookie Preferences